(17) identified three groups of breast cancer patients receiving aromatase inhibitors by principal component analysis, namely, the disease symptom cluster, treatment-related psychological symptom cluster, and gastrointestinal symptom cluster. This evidence concerns the gene CYP19A1 and breast cancer.